Skip to content
MarketScale
‹ Back to IndustriesSciences

Genes Versus Environment—Which is More Important? Tapping into this and Other Philosophical Evolutionary Questions

Human development isn’t as simple as genes plus environment. Just because we have certain genes doesn’t mean they are expressed—our early experiences in life can determine whether certain genes are turned “on” or “off,” according to Harvard. Rasmus Grønfeldt Winther, a scientist, researcher, writer, and educator, amongst other titles, has dived into this topic and…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Rasmus Winther · EvolutionGenesScience
Share

Key takeaways

01

Human development isn’t as simple as genes plus environment.

02

Just because we have certain genes doesn’t mean they are expressed—our early experiences in life can determine whether certain genes are turned “on” or “off,” according to Harvard.

03

Rasmus Grønfeldt Winther, a scientist, researcher, writer, and educator, amongst other titles, has dived into this topic and…

Human development isn’t as simple as genes plus environment. Just because we have certain genes doesn’t mean they are expressed—our early experiences in life can determine whether certain genes are turned “on” or “off,” according to Harvard. Rasmus Grønfeldt Winther, a scientist, researcher, writer, and educator, amongst other titles, has dived into this topic and other philosophical topics about human nature and evolution in his most recent publication.

Who are we and how did we come to be in existence? These are just some of the questions Rasmus Grønfeldt Winther seeks to answer in his 2022 publication Our Genes. This is only the start for Winther. As an experienced professor and accomplished publisher, he has written about topics including race and human genomic variation, remapping race, and varying views on evolution. Ultimately, by delving into these topics, he hopes to use population genetics and the philosophy of science to improve human communication and sustainable thinking.

So, how can we use such overarching philosophical questions to better improve the human race? Rasmus Grønfeldt Winther, Professor in the Humanities Division at the University of California, Santa Cruz, and author of Our Genes, provides insight into the “how” and “why” of humanity.

“Who are we? Who are you? Where do we come from as a species? Where might we be going? How did you come to be in body and mind? What is more important genes or the environment? How or how do they interact? These were questions. These are the questions that motivated me and inspired me to write my most recent book, Our Genes.

The subtitle of that book is a philosophical perspective on human evolutionary genomics. I wanted to start with the science of population genetics and with the methodology of statistics and ask philosophical and more general questions that might shed light on the philosophy of science and on how we can use science to understand ourselves better, to communicate with others, and to think more sustainably about where we’re going.”

About the author

RW
Rasmus Winther

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

RW
Rasmus Winther

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512